Caprion Teaming Up with Biomarkers Consortium to Study if Biomarkers Can Track Alzheimer’s Progression

Caprion Teaming Up with Biomarkers Consortium to Study if Biomarkers Can Track Alzheimer’s Progression
Caprion Biosciences Inc. is partnering with a public-private organization known as the Biomarkers Consortium to study whether biomarkers can be used to track changes in early Alzheimer’s disease progression. Researchers in the Cerebrospinal Fluid Proteomics Project will measure changes in protein concentration of certain biomarkers over time in Alzheimer's patients and people with mild cognitive impairment. The goal is to improve monitoring and treatment of cognitive impairment conditions. Lack of tools for determining early diagnosis and disease progression is a major challenge i
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *